Abstract 31P
Background
HRAS mutations have been found in 6% of HNSCCs. T cell exhaustion, defined as dysfunctional T cells stimulated by continuous antigen exposure. To guide immunotherapeutic approaches, we sought to assess the immune landscape of HRAS-mutant tumors by investigating the subpopulations of pre-exhausted and exhausted T cells.
Methods
We found 10 cases of HRAS mutant tumors and 39 cases of HRAS wild-type (WT) tumors. We sought to characterize exhausted CD8+ T cell subpopulations by measuring the expression of T-cell Factor-1 (TCF-1) and Programmed Cell Death-1 (PD-1) in the tumor's center (C) and periphery (P). Multiplex immunohistochemistry (IHC) was performed in FFPE tissue sections using three primary antibodies (PD1-CD8-TCF1/7), followed by analysis of a manually trained algorithm in Qupath software.
Results
HRAS mutant tumors present numerically higher numbers of total immune cells both in the C and the P than HRAS-WT tumors, that reached statistical significance only in the P (5123.17/mm2vs. 3527.93/mm2, p=0.002). In addition, the density of CD8+ T Cells was increased in both the C (694.10/mm2 vs. 356.02/mm2) and the P (851.10/mm2 vs. 333.30/mm2) in HRAS mutant tumors. Importantly, the percentage of pre-exhausted CD8 (+) T Cells was elevated in the P of HRAS mutant tumors (384.67/mm2vs. 51.18/mm2, p=0.040), indicating a possible association of response to ICB, since pre-exhausted T cells mediate the proliferative response to immunotherapy. On the contrary, exhausted T cells, defined as PD-1(+)TCF-1 (-) were more abundant in the C of HRAS mutant tumors compared to WT (13.77% vs. 2.67% of total CD8+ cells, p=0.022). Moreover, increased area occupied by CD11c+ dendritic cells and numbers of CD8+ T cells were found in regional lymph nodes from HRAS mutant patients (79.25% vs 38.80%, p=0.036 and 10160.43 vs 4438.28/mm2, p=0.036, respectively), consistent with data showing that maintenance of TCF1 by intratumoral T cells requires continuous migration from draining lymph nodes.
Conclusions
Pre-exhausted PD-1(+)TCF-1(+) T cells are significantly increased at the periphery of HRAS mutant tumors, suggesting a potential sensitivity of these tumors to ICB.
Legal entity responsible for the study
The authors.
Funding
Kura Oncology.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
190P - Immune-related roles of B7H3 in glioblastoma
Presenter: Arnaud Simonet
Session: Poster Display
191P - Senolytic treatment remodels glioblastoma microenvironment
Presenter: Alexa Saliou
Session: Poster Display
192P - Analysis of Tumor-Associated Macrophages and Tumor-infiltrating Lymphocytes within the Tumor Microenvironment of Primary Tumors and Matched Brain Metastases
Presenter: Markus Kleinberger
Session: Poster Display
193P - Engagement of sialylated glycans with Siglec receptors on suppressive myeloid cells inhibit anti-cancer immunity via CCL2
Presenter: Ronja Wieboldt
Session: Poster Display
194P - Achieving Reproducible Maturation Staging of Tertiary Lymphoid Structures: from Imaging Mass Cytometry Data to Pathology Applications
Presenter: Marion Le Rochais
Session: Poster Display
195P - IMMUcan - Toward a better understanding of the tumor microenvironment to inform precision oncology approaches.
Presenter: Marie Morfouace
Session: Poster Display
196P - Local glycan engineering induces systemic antitumor immune reactions via antigen cross-presentation
Presenter: Natalia Rodrigues Mantuano
Session: Poster Display
197P - Computational pathology pipeline enables quantification of intratumor heterogeneity and tumor-infiltrating lymphocyte score
Presenter: Daniel Tiezzi
Session: Poster Display
198P - Polarization of tumor-associated macrophages enhanced by 2-HP-_-cyclodextrin modified PLGA nanoparticles
Presenter: HAO YUAN
Session: Poster Display
199P - Scalable multiplexed image analysis across cancer types as part of the IMMUcan consortium
Presenter: Nils Eling
Session: Poster Display